D
David Fitz-Patrick
Publications - 3
Citations - 245
David Fitz-Patrick is an academic researcher. The author has contributed to research in topics: Gout & Allopurinol. The author has an hindex of 3, co-authored 3 publications receiving 201 citations.
Papers
More filters
Journal ArticleDOI
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)
Kenneth G. Saag,David Fitz-Patrick,J. Kopicko,Maple Fung,Nihar Bhakta,Scott Adler,C. Storgard,Scott Baumgartner,Michael Becker +8 more
TL;DR: The Combining Lesinurad with Allopurinol Standard of Care in Inadequate Responders (CLEAR 1) study, a 12‐month, multicenter, randomized, double‐blind, placebo‐controlled phase III trial, was conducted to investigate daily lesinur ad added to allopur inol versus placebo plus allopURinol in patients with serum urate (UA) levels above a target of <6.0 mg/dl.
Journal ArticleDOI
An open-label, 6-month study of allopurinol safety in gout: The LASSO study
Michael Becker,David Fitz-Patrick,Hyon K. Choi,Nicola Dalbeth,C. Storgard,Matt Cravets,Scott Baumgartner +6 more
TL;DR: This large multicenter study of allopurinol dose-titration strategy was well tolerated, without new safety signals emerging over 6 months, but despite encouragement to treat to target, significant proportions of patients did not achieve target sUA.
Journal ArticleDOI
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials
David Fitz-Patrick,Kent Roberson,Kiyoshi Niwa,Takabumi Fujimura,Koji Mori,Jesse Hall,Xiaohong Yan,Zancong Shen,Sha Liu,Yasushi Ito,Scott Baumgartner +10 more
TL;DR: Verinurad monotherapy resulted in sustained reductions in sUA in Japanese/US patients but renal AEs occurred, so verinURad alone is not recommended for treatment of hyperuricemia or gout.